Salute e Benessere

A first of its kind Virtual Gynecology and Obstetrics Hospital is using…

Sheba Beyond is working with cutting-edge Israeli MedTech companies and integrates various remote telehealth solutions including thePulsenmore home ultrasound solution, that allows the replacement of in person visits with remote ones. Sheba Beyond is working with cutting-edge Israeli MedTech companies and integrates various remote telehealth solutions including thePulsenmore home ultrasound solution, that allows the replacement of in person visits with remote ones. The Pulsenmore home...

Pharming announces sale of priority review voucher

Pursuant to the terms of the August 2019 exclusive license agreement between Pharming and Novartis for leniolisib, Novartis has the right to purchase the PRV from Pharming for a pre-agreed, contractually defined percentage of the PRV value. Pursuant to the terms of theAugust 2019exclusive license agreement between Pharming and Novartis for leniolisib, Novartis has the right to purchase the PRV from Pharming for a pre-agreed, contractually defined percentage of the PRV value. Jeroen...

Ipsen SA initiates a share buy-back program to cover its free employee…

REGULATED INFORMATIONIpsen initiates a share buy-back program to cover itsfree employee share-allocation planParis (France), 1June 2023- Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 350,000, or about 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen's free employee...

BioSenic SA : Information on the total number of voting rights and shares

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June1 st, 2023 , 7 .00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs). The following information is...

Redwood Pharma presents positive results from a clinical study with RP501…

RP501 achieved a statistically significant effect on several of the 10 subjective measurement parameters in the study, such as burning sensation, stinging and itching in the eye. The results also show that the product is safe and well-tolerated. The product's ease of use is also perceived positively by a majority of the test subjects. RP501achieved a statistically significant effect on several of the 10 subjective measurement parameters in the study, such as burning sensation, stinging and...

Santhera Publishes Annual Report 2022

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31 , 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022.Santhera's Annual Report 2022 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2022, and confirms the preliminary unaudited 2022 annual...

Telesis Bio Secures Financing of $28.0 Million

Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital PartnersSAN DIEGO, May31, 2023(GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional...

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating…

B-cell Non-Hodgkin lymphoma (B-NHL) remains one of the most common cancers worldwide, with reports an estimate of 544,000 new cases and 260,000 deaths worldwide in 2020. Despite the groundbreaking efficacy of current CAR T-cell therapies, studies on patients treated with autologous CAR T-cells are revealing several causes for relapses that includes: antigen loss, low antigen expression or insufficient CAR T-cell potency and persistence, among others. While several suitable targets to treat...

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Exclusive worldwide rights licensed from Seal Rock Therapeutics forinjectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence supportASK1 inhibition as a relevant therapeutic strategy in multi-system disorders such as Acute-on-Chronic Liver Failure (ACLF)First-in-Human study planned in the second half of 2024 to support a Proof-of-Concept study in ACLF patients as early...

Innocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues…

Financial highlights for the first quarter of 2023 Financial highlights for the first quarter of 2023 Revenue : The Company generated approximatelyUS$1.6M in revenue for the quarter endedMarch 31, 2023, representing aUS$1.3Mincrease, compared to the first quarter of 2022. This increase in revenue growth is mainly due to the increased sales of Innocan's subsidiary, B.I. Sky Global Ltd. Gross Profit : The Company saw approximately US$1.4M in gross profit for the quarter...

Alkermes to Participate in Two Upcoming Investor Conferences

Goldman Sachs 44th Annual Global Healthcare ConferenceDate/Time:Monday, June 12, 2023 at 9:20 a.m. PDT (12:20 p.m. EDT/5:20 p.m. BST) Goldman Sachs 44 thAnnual Global Healthcare Conference Date/Time:Monday, June 12, 2023at9:20 a.m. PDT( 12:20 p.m. EDT / 5:20 p.m. BST ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company...

Global Door Closer and Exit Devices Market to be Worth $4.76 Billion by 2028…

Browse In-Depth TOC on the Door Closer and Exit Devices Market Browse In-Depth TOC on the Door Closer and Exit Devices Market 466 – Pages 190 - Tables 246 - Charts The global door closer and exit device market is poised for significant growth during the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 4.72%. This growth can be attributed to the increasing demand for door closers in new construction projects and the growing trend of renovating...

InDex Pharmaceuticals' investor call at 15:00 CET on June 1

If you wish to attend the call, please log in at: https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZDZlODIzY2QtYzk2NC00NDY0LTkwNjctMTcwZDNhMTE0YTAx%40thread.v2/0?context=%7b%22Tid%22%3a%2279027c63-7166-4893-aab5-150a26f6aa50%22%2c%22Oid%22%3a%22bc0dd025-f6fb-4ac2-b41e-0d5e02e053e5%22%7d If you wish to attend the call, please log in at:...

InDex Pharmaceuticals announces license agreement with Viatris Japan to develop…

InDex will continue to fund all development which incorporates the completion of the global phase III-program CONCLUDE, including a cohort of Japanese patients in Induction Study 2 and a PK study in Japanese patients prior to filing. Viatris Japan will fund all regulatory and commercialization expenses, as well as any additional Japanese-specific studies required in Japan. InDex will continue to fund all development which incorporates the completion of the global phase III-program CONCLUDE,...

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 22convertible bonds in Oxurion resulting in a EUR 550 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...

Proteomics Market worth $72.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=731 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=731 Browse in-depth TOC on "Proteomics Market" 707 - Tables 49 - Figures 604 - Pages Proteomics Market Scope: Spectroscopy accounted for the largest share of the instrumentation technologies segment in the proteomics market in 2022. Based on instrumentation technologies, the...

Defibrillator Market Is Projected to Reach USD 24,608.3 Million by 2030…

Download Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-1W72/Defibrillators_Market Download Free Sample : https://reports.valuates.com/request/sample/ALLI-Auto-1W72/Defibrillators_Market Major factors driving the Growth of the Defibrillators Market Public and private organizations' increasing attention to public access defibrillators (PAD) has spurred market expansion. Additionally, a rapidly expanding elderly population with a high risk of cardiac arrest, an...

DanCann Pharma A/S publishes Q1-2023 report

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments: "I am delighted to provide an update on the progress and developments of DanCann Pharma during the first quarter of 2023...

Ipsen S.A. - Combined Shareholders' Meeting of Ipsen S.A. held on 31 May 2023

REGULATED INFORMATION COMBINED SHAREHOLDERS' MEETING OF IPSEN S.A. HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS' VOTE HAVE BEEN APPROVED Paris (France), 31 May 2023– The Combined Shareholders' Meeting of IPSEN S.A. (Euronext: IPN; ADR: IPSEY) was held today at theSalons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna , 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors and meeting...

Sanitary Pumps and Valves Market worth $2.5 billion by 2028 - Exclusive Report…

Browse in-depth TOC on "Sanitary Pumps and Valves Market" 159 – Tables73 – Figures233 – Pages Browse in-depth TOC on "Sanitary Pumps and Valves Market" 159 – Tables 73 – Figures 233 – Pages Sanitary Pumps and Valves Market Report Scope: The positive displacement pump type segment is expected to grow at the highest CAGR during the forecast period. Positive displacement pumps are well known in the sanitary pumps and valves market for their ability to transfer the high...

ivWatch Expands Global Footprint into the United Kingdom

ivWatch is also announcing the appointment of Helen Stephens to the executive team as Vice President of Sales for Europe, Middle East, and Africa (EMEA). Helen has a tenured 30-year diverse career, as a nurse at the bedside and with experience in medical device sales at companies including Becton Dickinson, Vygon, Smiths Medical, and most recently ICU Medical. Stephens will provide a wealth of knowledge to drive growth in the EMEA region and select other global high-demand markets. She will…

Total number of shares and voting rights in Zealand Pharma at May 31, 2023

Company announcement – No. 24 / 2023 Total number of shares and voting rights in Zealand Pharma at May 31, 2023 Copenhagen, Denmark, May 31, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a...

Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting…

Coming off a big win in December 2022 that saw their lead asset pelareorep gain FDA Fast Track Designation for the treatment of advanced/metastatic pancreatic cancer, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is set to once again deliver results on their flagship immunotherapeutic agent. At the 2023 ASCO Annual Meeting, Oncolytics will be making the company's first oral presentation at the event, this time giving an update on its randomized BRACELET-1 trial in HR+/HER2- metastatic…

CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major…

Key Takeaways from the CTLA-4 Inhibitors Competitive Landscape Report Key Takeaways from the CTLA-4 Inhibitors Competitive Landscape Report Request a sample and discover the recent advances in CTLA-4 inhibitors @CTLA-4 Inhibitors Competitive Landscape Report CTLA-4 Inhibitors Overview CTLA-4 (cytotoxic T lymphocyte antigen-4) is a key negative regulator of T cell activation. The well-defined B7:CD28/CTLA-4 pathway controls the production and maintenance of immune responses...

Altri Comunicati